SYNTHESIS OF L-2-DEOXYTHREOSE NUCLEOSIDES AS POTENTIAL ANTIVIRAL AGENTS

Kiran S. Toti and Serge Van Calenbergh[*]

Laboratory for Medicinal Chemistry (FFW), Ghent University, Harelbekestraat 72, 9000 Gent, Belgium.

Several nucleoside analogs are well-known to inhibit the reverse transcription (RT) process in HIV by terminating the synthesis of a proviral DNA strand. Recently, Herdewijn and coworkers showed that some L-2-deoxythreose nucleoside phosphonates (**a**; Figure 1) selectively inhibit HIV without affecting human DNA synthesis.[1] These nucleoside analogues require two additional phosphorylation steps by cellular kinases before they are incorporated in the viral genome and lead to chain termination. It is believed that a *cis* orientation of the base and the 3'-substituent is a structural requirement for optimal conversion to the diphosphate. Inspired by these findings, we decided to explore the antiviral properties of the threose-based nucleoside analogues (**b**; Figure 1), which are anticipated to have superior bioavailability compared to the parent phosphonates. Remarkably, such α-L-2'-deoxythreofuranosyl analogues (exhibiting a 1'R,3'R configuration) have not been reported before.

Fig. 1



B = Natural/ Modified Bases

The synthesis of the desired T, U, C and A analogs (Scheme-**1**), involving a Vorbrüggen coupling and a Barton-McCombie deoxygenation, will be described.

Scheme-1



---

(1) (a) Wu, T.; Froeyen, M.; Kempeneers, V.; Pannecouque, C.; Wang, J.; Busson, R.; De Clercq, E.; Herdewijn, P. *J. Am. Chem. Soc*. **2005**, 127, 5056-5065. (b) Vina, D.; Wu, T.; Renders, M.; Laflammeb, G.; Herdewijn, P. *Tetrahedron,* **2007,** 63, 2634–2646.

(2) Hernández-Garcıá, L.; Quintero, L.; Sánchez, M.; Sartillo-Piscil, F. *J. Org. Chem.* **2007**, *72*, 8196-8201.

(3) Smith, A. B III.; Sulikowski, G. A.; Sulikowski, M. M.; Fujimoto, K. *J. Am. Chem. Soc.* **1992**, 114, 2567-2576.